PurposePatients with hemoglobin SC (Hb SC) and hemoglobin SB+ (Hb SB+) thalassemia suffer from frequent hospitalizations yet strong evidence of a clinical benefit of hydroxyurea (HU) in this population is lacking. Patients with recurrent hospitalizations for pain crisis are offered HU at our institution based on small cohort data and anecdotal benefit. This study identifies outcomes from a large cohort of patients with Hb SC and SB+ thalassemia who were treated with HU for 2 years.Materials and methodsA retrospective review was conducted of 32 patients with Hb SC and SB+ thalassemia who were treated with HU. We reviewed the number, and reasons for hospitalization in the 2 years prior to, and 2 years post-HU treatment as well as laboratory changes from baseline, over 1 year.ResultsPatients with Hb SC and SB+ thalassemia started on HU for frequent pain, had a significant reduction in hospitalizations over 2 years as compared to the 2 years prior to HU initiation (mean total hospitalizations/year: pre-HU: 1.6 vs post-HU 0.4 hospitalizations, P<0.001; mean pain hospitalizations/year: pre-HU 1.5 vs post-HU 0.3 hospitalizations, P<0.001). Patients demonstrated hematologic changes including an increase in percent fetal hemoglobin (%HbF) pre–post HU (4.5% to 7.7%, P=0.002), mean corpuscular volume (74 to 86 fL, P<0,0001), and decrease in absolute neutrophil count (5.0 to 3.2×109/L, P=0.007). Patients with higher doses of HU demonstrated the greatest reduction in hospitalizations but this was unrelated to absolute neutrophil count.ConclusionThis cohort of patients with Hb SC and SB+ thalassemia provides additional support for using HU in patients with recurrent hospitalizations for pain. A large randomized multicenter trial of HU to reduce pain admissions should be conducted to confirm these data and provide much needed evidence based recommendations for this population.
Background: The effects of hydroxyurea in clinically severe hemoglobin SC (Hb SC) and hemoglobin Sβ+ thalassemia patients (Hb Sβ+) are not well defined. The largest previous report reviewed 15 children with Hb SC treated with hydroxyurea (Yates, et al: Pediatr Blood Cancer 2013;60: 323-325). Prior studies describe a mixed hematologic pattern of response, but all pediatric reports show an increase in fetal hemoglobin and MCV in Hb SC. To further evaluate the hematologic effect of hydroxyurea in these compound heterozygous conditions, we reviewed 27 patients with Hb SC and 7 with Hb Sβ+ treated to date at our institution Methods: The medical records of all children treated at least a year with hydroxyurea for clinically severe Hb SC and Hb Sβ+ were reviewed. Age at start and indication for hydroxyurea were documented. Laboratory values were recorded at hydroxyurea start and at the visit that fell closest to one year of therapy. Data collected included hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), white blood cell count (WBC), absolute neutrophil count (ANC), platelet count (PLT), absolute reticulocyte count (ARC), hemoglobin F % (Hb F), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and total bilirubin. The milligram/kilogram dose of hydroxyurea was recorded at start and at 12 months of treatment. Paired differences were compared at baseline and 12 months of treatment. Results: The average age at hydroxyurea start for patients with Hb SC was 9.4 years + 3.8. Fifteen of the 27 patients were male. Hb Sβ+ patients’ average age at start was 10.7 years + 6.9. Five of the 7 Hb Sβ+ patients were male. Twenty-six of the 27 patients with Hb SC were treated with hydroxyurea for recurrent painful crises and one Hb SC patient started hydroxyurea for recurrent acute chest syndrome. All 7 Hb Sβ+ patients were treated with hydroxyurea due to recurrent painful crises. The average dose of hydroxyurea for Hb SC patients was 22 mg/kg/day and 21mg/kg/day for the Hb Sβ+ group. There was no significant change in mg/kg dose from hydroxyurea start to the 12 month interval. For patients with Hb SC, significant decreases were seen in the following lab values with p values noted in parenthesis: WBC (0.0001), PLT (0.0122), ARC (0.0002) , ANC (0.0002) and AST(0.0408). Significant increases were seen in MCV (0.0003) and Hb F (0.0181). However, Hb F and MCV values in Hb SC patients (average Hb F of 7.4% (+5.8%) and MCV of 87 fl (+14) after 12 months of treatment) were not as high as seen in good hydroxyurea responders with Hb SS disease Hb, Hct and bilirubin did not significantly change in patients with Hb SC. For Hb Sβ+, statistically significant decreases were seen in WBC (0.0157), PLT (0.0476), and ANC (0.0047). MCV also increased in Hb SB+ from 70 fl (+6.63) at baseline to 80 fl (+5.4) at 12 months (p= 0.0054). Hb F did not change in HbSβ+ patients with values of 7% (+ 4.2) at baseline and 9.5% (+ 5) at 12 months (p= 0.4042). Similar to the Hb SC group, Hb and Hct did not significantly increase in the Hb Sβ+ patients. Conclusions: This report of the largest pediatric cohort of Hb SC and Hb Sβ+ patients treated with hydroxyrea to date shows hematologic effect, although with some differences from typical response in patients with Hb SS disease. Most notably, Hb and Hct did not change in either group which is important given concerns about viscosity increase in patients with higher baseline values. Further study in larger numbers of patients is needed to evaluate hematologic effect and clinical outcome. Disclosures No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.